HC Wainwright Analysts Boost Earnings Estimates for BriaCell Therapeutics Corp. (NASDAQ:BCTX)

Posted by MarketBeat News on Sep 24th, 2024

BriaCell Therapeutics Corp. (NASDAQ:BCTX – Free Report) – Equities researchers at HC Wainwright boosted their FY2024 earnings estimates for shares of BriaCell Therapeutics in a research report issued on Thursday, September 19th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.80) per share for the year, up from their prior estimate of ($1.39). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for BriaCell Therapeutics’ current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for BriaCell Therapeutics’ Q4 2024 earnings at ($0.52) EPS, FY2025 earnings at ($0.26) EPS, FY2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.19) EPS and FY2028 earnings at ($0.12) EPS.

BriaCell Therapeutics Stock Performance

Shares of BCTX opened at $0.68 on Monday. The business’s fifty day moving average is $0.69 and its 200-day moving average is $1.49. The firm has a market cap of $12.47 million, a price-to-earnings ratio of -0.55 and a beta of 1.31. BriaCell Therapeutics has a 52-week low of $0.46 and a 52-week high of $6.36.

Institutional Investors Weigh In On BriaCell Therapeutics

Want More Great Investing Ideas?

A hedge fund recently raised its stake in BriaCell Therapeutics stock. K.J. Harrison & Partners Inc lifted its position in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX – Free Report) by 7.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 87,044 shares of the company’s stock after purchasing an additional 6,329 shares during the period. K.J. Harrison & Partners Inc owned about 0.54% of BriaCell Therapeutics worth $249,000 as of its most recent filing with the Securities and Exchange Commission. 15.42% of the stock is currently owned by institutional investors.

About BriaCell Therapeutics

(Get Free Report)

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.